Coherus Oncology provides preliminary FY2025 revenue and cash at J.P. Morgan conference

Coherus Oncology, Inc.

Filing furnishes preliminary unaudited net revenues for Q4 and FY2025 ended Dec 31, 2025.
Preliminary cash, cash equivalents and investments as of Dec 31, 2025 also disclosed.
Slide includes forward-looking projection of LOQTORZI revenue growth.
Actual final results may differ materially; independent auditor has not reviewed these preliminary figures.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.